Anagenics

Anagenics is a health and beauty technology company headquartered in Australia that specializes in anti-aging solutions for hair and skin. The company's core scientific focus is the inhibition of Fibroblast Growth Factor 5 (FGF5), a key regulator that signals hair follicles to stop growing and enter the fall-out phase. Anagenics commercializes this research through its Advangen subsidiary, which produces the évolis brand of clinically validated topical hair growth treatments. Beyond its proprietary R&D, the company also operates BLC Cosmetics, a premium distribution business for global wellness and skincare brands. Anagenics is publicly traded on the Australian Securities Exchange under the ticker AN1.